Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting
Aktis Oncology (AKTS) is assigned a 'Buy' rating due to its innovative miniprotein radioconjugate technology targeting Nectin-4 and B7-H3 for solid tumors. The company’s use of actinium-225 aims to broaden radiopharmaceutical applications beyond traditional targets like PSMA and SSTR2. With $562.1 million in cash post-IPO, Aktis is funded through 2029, supporting upcoming catalysts including phase 1b data for AKY-1189 in 2027 and mid-2026 developments for AKY-2519. Its pipeline has potential to expand the reach of targeted radiotherapies in oncology.
- ▪Aktis Oncology is initiated with a 'Buy' rating based on its novel miniprotein radioconjugates for solid tumor treatment.
- ▪The company is developing therapies targeting Nectin-4 and B7-H3 using alpha-emitting actinium-225 isotopes.
- ▪Key upcoming milestones include phase 1b Part 1 data for AKY-1189 expected in Q1 2027 and ASCO presentations for AKY-2519 in mid-2026.
- ▪Aktis Oncology has $562.1 million in pro forma cash after its IPO, providing funding into 2029.
- ▪The company aims to expand the radiopharmaceutical market beyond current standards like PSMA and SSTR2.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895322-aktis-oncology-buy-radiotherapeutic-isotope-design-for-broad-targeting"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
